Tenax Therapeutics faces securities fraud class action
Alpha Vantage · The National Law Review · · AI-summarised by FinFlash
A securities class action has been filed against Tenax Therapeutics (NASDAQ: TENX) on behalf of investors who bought shares between November 13, 2023 and August 7, 2026. The suit alleges misleading statements about the effectiveness and commercial prospects of drug TNX-103 after its Phase 3 LEVEL trial missed primary and key secondary endpoints, triggering a sharp stock decline.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.